Image
Call a Colleague

Making the Call in Heart Failure

Multidimensional Outcomes With SGLT2 Inhibitors

Meeting Slides

Suggested Readings

Heart disease and stroke statistics-2020 update: a report from the American Heart Association.

Virani et al. Circulation. 2020;141(9):e139-e596.

How should we sequence the treatments for heart failure and a reduced ejection fraction?: a redefinition of evidence-based medicine.

McMurray et al. Circulation. 2021;143(9):875-877.

Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.

Zinman B, et al. N Engl J Med. 2015;373(22):2117-2128.

Canagliflozin and cardiovascular and renal events in type 2 diabetes.

Neal B, et al. N Engl J Med. 2017;377(7):644-657.

Dapagliflozin and cardiovascular outcomes in type 2 diabetes.

Wiviott SD, et al. N Engl J Med. 2019;380(4):347-357.

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.

Perkovic V, et al. N Engl J Med. 2019;380(24):2295-2306.

Cardiovascular outcomes with ertugliflozin in type 2 diabetes.

Cannon CP, et al. N Engl J Med. 2020;383(15):1425-1435.

Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis.

McGuire D, et al. JAMA Cardiol. 2021;6(2):148–158.

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.

Zannad F, et al. Lancet. 2020;396:819-829.

Empagliflozin in heart failure with a preserved ejection fraction.

Anker et al. N Engl J Med. 2021;385(16):1451-1461.

Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.

Solomon et al. N Engl J Med. 2022;387(12):1089-1098.

Activity
Activity for event:Making the Call in Heart Failure:

Multidimensional Outcomes with SGLT2 Inhibitors

Activity
Making the Call in Heart Failure

Multidimensional Outcomes with SGLT2 Inhibitors

Relevant Resources

Incretin-Based Therapies for Type 2 Diabetes

Mechanism-Based Strategies to Achieve Patient-Centered Care

Insulin Replacement Therapy for Type 2 Diabetes

Patient-Centered Management of Hyperglycemia in Primary Care

Improving Outcomes in Type 2 Diabetes

Integrating GLP-1 Receptor Agonists Into Multimodal Treatment Regimens

A Focus on Bipolar Depression

Overcoming Diagnostic Barriers and Optimizing Long-Term Patient Outcomes

Clinical Issues in Type 2 Diabetes

Discussions and Debates Around GLP-1 Receptor Agonists

Clinical Issues in Type 2 Diabetes

Evolving Roles of GLP-1 Receptor Agonists

Improving Outcomes for Women with Type 2 Diabetes

Individualizing Evidence-Based Care

Noninsulin Approaches to Managing Type 2 Diabetes

Best Practices in Combination Therapy

Hitting the Target in Type 2 Diabetes

Evolving Approaches to Insulin Based Therapy

Improving Outcomes in Congenital and Acquired Lipodystrophy

Best Practices in Diagnosis and Management

Clinical Updates in Type 2 Diabetes

New Strategies for Insulin Replacement Therapy

Clinical Issues in Type 2 Diabetes

Consensus and Controversies Around Intensifying Noninsulin Therapy

How Low Do You Go?

Clinical Updates in LDL-C Management

Incretin-Based Therapies For Type 2 Diabetes

Improving Comprehensive Patient Care

Clinical Updates in Type 2 Diabetes

An Evolving Role for Combinations of Injectable Antihyperglycemic Therapies

Raising the Bar by Lowering the Target

Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management

Injecting New Ideas into Managing Type 2 Diabetes

Evolving Roles of GLP-1 Receptor Agonists

Multidimensional Issues in Type 2 Diabetes

Looking Beyond Hemoglobin A1c

GLP-1 Receptors Agonists in Type 2 Diabetes

Mechanistic Insights and Evolving Treatment Options

Pharmaceutical Economics and LDL-C Management

Implications for PCSK9 Inhibitors in Clinical Practice

Assimilating the Evidence in T2DM

Cardiovascular and Renal Outcomes With SGLT2 Inhibitors

Getting Low in Familial Hypercholesterolemia

Reducing LDL-C and a Lifetime of Cardiovascular Risk

Anemia in Chronic Kidney Disease

New Avenues to Improve Patient Outcomes